Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AC Immune SA

www.acimmune.com

Latest From AC Immune SA

Another Alzheimer's Setback As Roche And Lilly Drugs Fail

As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.

Neurology Clinical Trials

What The New Decade Could Bring For Alzheimer’s Treatment

Dementia is one of the world’s greatest health care challenges. Globally, there is a new case of dementia every three seconds, adding up to around 50 million people worldwide. While it is good news that people are living longer, healthier lives, by 2050 the number of people with dementia is predicted to more than triple, reaching around 152 million.

Research and Development Strategies Innovation

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Clinical Trials Neurology

AC Immune CEO Outlines ‘Roadmap’ For Fighting Alzheimer’s

AC Immune’s CEO tells Scrip that treating earlier, targeting Tau, and focusing on more homogeneous populations will be needed to successfully fight Alzheimer’s Disease.

Companies Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
    • Vaccines
  • Therapeutic Areas
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • AC Immune SA
  • Senior Management
  • Andrea Pfeifer, PhD, CEO
    Joerg Hornstein, CFO
    Andreas Muhs, PhD, CSO
  • Contact Info
  • AC Immune SA
    Phone: (41) 21 693 91 21
    EPFL Innovation Park
    Bldg. B
    Lausanne, 1015
    Switzerland
UsernamePublicRestriction

Register